Total polysaccharides of the Sijunzi decoction attenuate tumor necrosis factor-α-induced damage to the barrier function of a Caco-2 cell monolayer via the nuclear factor-κB-myosin light chain kinase-myosin light chain pathway.

Total polysaccharides of the Sijunzi decoction attenuate tumor necrosis factor-α-induced damage to the barrier function of a Caco-2 cell monolayer via the nuclear factor-κB-myosin light chain kinase-myosin light chain pathway. World J Gastroenterol. 2018 Jul 14;24(26):2867-2877 Authors: Lu Y, Li L, Zhang JW, Zhong XQ, Wei JA, Han L Abstract AIM: To explore the protective effects and underlying mechanisms of total polysaccharides of the Sijunzi decoction (TPSJ) on the epithelial barriers in vitro. METHODS: Caco-2 cell monolayers were treated with or without TPSJ in the presence or absence of TNF-α,…

Read More

Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα).

Related Articles Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα). World J Gastroenterol. 2018 Jul 07;24(25):2764-2775 Authors: Cao BL, Qasem A, Sharp RC, Abdelli LS, Naser SA Abstract AIM: To perform a meta-analysis on the risk of developing Mycobacterium tuberculosis (TB) infection in Crohn’s disease (CD) patients treated with tumor necrosis factor-alpha (TNFα) inhibitors. METHODS: A meta-analysis of randomized, double-blind, placebo-controlled trials of TNFα inhibitors for treatment of CD in adults was conducted. Arcsine transformation of TB incidence…

Read More

Current global trends in the incidence of pediatric-onset inflammatory bowel disease.

Related Articles Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018 Jul 07;24(25):2741-2763 Authors: Sýkora J, Pomahačová R, Kreslová M, Cvalínová D, Štych P, Schwarz J Abstract AIM: To perform a comprehensive review and provide an up-to-date synopsis of the incidence and trends of inflammatory bowel disease (IBD). METHODS: We systematically searched the MEDLINE (source PubMed), EMBASE and Cochrane Library databases in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (period: 1985-2018) to identify studies reporting population-based data on the…

Read More

Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends.

Related Articles Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends. World J Gastroenterol. 2018 Jul 07;24(25):2673-2685 Authors: Mijan MA, Lim BO Abstract Inflammatory bowel disease (IBD) is a serious health concern among western societies. The disease is also on the rise in some East Asian countries and in Australia. Health professionals and dietitians around the world are facing an unprecedented challenge to prevent and control the increasing prevalence of IBD. The current therapeutic strategy that includes drugs and biological treatments is…

Read More

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.

Related Articles Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol. 2018 Jun 21;24(23):2457-2467 Authors: Scribano ML Abstract The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action that acts on different inflammatory pathways involved in IBD pathogenesis is appealing. Vedolizumab is a fully humanised monoclonal antibody that selectively targets α4β7 integrin. Based on…

Read More

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?

Related Articles Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol. 2018 Jun 14;24(22):2363-2372 Authors: Strohl M, Gonczi L, Kurt Z, Bessissow T, Lakatos PL Abstract Inflammatory bowel disease (IBD) is a lifelong, progressive disease that has disabling impacts on patient’s lives. Given the complex nature of the diagnosis of IBD and its management there is consequently a large economic burden seen across all health care systems. Quality indicators (QI) have been created to assess the different façades of disease management…

Read More

Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.

Related Articles Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature. World J Gastroenterol. 2018 Jun 07;24(21):2320-2326 Authors: Hvas CL, Ott P, Paine P, Lal S, Jørgensen SP, Dahlerup JF Abstract Bile acid diarrhea results from excessive amounts of bile acids entering the colon due to hepatic overexcretion of bile acids or bile acid malabsorption in the terminal ileum. The main therapies include bile acid sequestrants, such as colestyramine and colesevelam, which may be given in combination with the opioid receptor…

Read More

Magnetic resonance imaging and Crohn’s disease endoscopic index of severity: Correlations and concordance.

Related Articles Magnetic resonance imaging and Crohn’s disease endoscopic index of severity: Correlations and concordance. World J Gastroenterol. 2018 Jun 07;24(21):2279-2290 Authors: Zhu NY, Zhao XS, Miao F Abstract AIM: To examine the correlation between magnetic resonance imaging (MRI) and endoscopic index of severity (CDEIS) in patients with Crohn’s disease (CD). METHODS: This was a retrospective study of 104 patients with CD that were treated at the Ruijin Hospital between March 2015 and May 2016. Among them, 61 patients with active CD were evaluated before/after treatment. MRI and endoscopy were…

Read More

Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn’s disease.

Related Articles Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn’s disease. World J Gastroenterol. 2018 May 14;24(18):2036-2046 Authors: Gupta N, Lustig RH, Chao C, Vittinghoff E, Andrews H, Leu CS Abstract AIM: To determine the distribution of anthropometric parameter (AP)-z-scores and characterize associations between medications/serum biomarkers and AP-z-scores in pediatric Crohn’s disease (CD). METHODS: CD patients [< chronological age (CA) 21 years] were enrolled in a cross-sectional study. Descriptive statistics were generated for participants’ demographic characteristics and key variables of interest. Paired t-tests were used to compare AP-z-scores…

Read More

Olfactomedin-4 in digestive diseases: A mini-review.

Related Articles Olfactomedin-4 in digestive diseases: A mini-review. World J Gastroenterol. 2018 May 07;24(17):1881-1887 Authors: Wang XY, Chen SH, Zhang YN, Xu CF Abstract Olfactomedin-4 (OLFM4, GW112, hGC-1) is a glycoprotein belonging to the olfactomedin family. The expression of OLFM4 is strong in the small intestine, colon and prostate, and moderate in the stomach and bone marrow. Previous studies have revealed that OLFM4 is closely associated with many digestive diseases. Up-regulation of OLFM4 has been detected in the Helicobacter pylori (H. pylori)-infected gastric mucosa, inflammatory bowel disease tissue and gastrointestinal…

Read More
<< Go Back